#Genetherapy
🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TWN9KM #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT
November 18, 2026 at 9:00 AM
Exogenus Therapeutics adopts standardized assays for EV batch testing.

🔗 Read the full story on GazeWire

#Biotech #Crispr #GeneTherapy #GazeWire
Exogenus Therapeutics adopts standardized assays for EV batch testing.
Exogenus Taps ELISA and Western Blot Panel to Streamline EV Batch Testing
gazewire.com
November 19, 2026 at 1:15 AM
🧬 Beta Thalassemia Treatment Market to reach USD 6.84 billion by 2034, growing at 6.94% CAGR.

🌏 Asia Pacific led with 37.2% market share in 2025.

📊 Get More Info: straitsresearch.com/report/beta-...

#BetaThalassemia #GeneTherapy #HealthcareMarket #StraitsResearch
November 17, 2026 at 10:05 AM
November 15, 2026
👉 A new gene-editing approach could transform the treatment of sickle cell disease!
🙂 Another encouraging news from Groupe UIG.
Read: lnkd.in/ge8y4m5Z
#BaseEditing #GeneEditing #GeneTherapy #SickleCellDisease
November 15, 2026 at 2:25 PM
🧬 Gene therapies instruct cells to produce a specific protein, but regulating the amount of protein is a challenge. Short RNA adaptamers allow precise control over protein synthesis when bound to specific small-molecule drugs, acting as molecular switches.

#MolecularBiology #GeneTherapy #SciComm
November 18, 2026 at 12:00 PM
“It is not enough to be a great scientist. You need everybody.”
In our new #GeneH video, partners explain why #GeneTherapy needs the 4-helix model:
academia, industry, public authorities, clinicians, patients and society working together.
Watch: youtu.be/nfRgmL49VSo?...
#4Helix
@kemijski.bsky.social
November 16, 2026 at 9:36 AM
Congratulations to M.D.-Ph.D. student Kijung Kwak, who received a 2026 PhRMAfoundation fellowship to advance a new approach to gene therapy for Parkinson’s disease in the UMSOM lab of Jung Soo Suk, PhD.
https://ow.ly/AiWU5105Vu1
#Parkinsons #GeneTherapy

November 12, 2026 at 2:00 PM
📰 Alcohol Dampens Cancer Immunotherapy Efficacy in Preclinical Study

A new study reveals that moderate-to-heavy alcohol consumption cuts the effectiveness of anti-PD-1 immunotherapy by half in animal models.

🔗 Read the full story on GazeWire

#Biotech #Crispr #GeneTherapy #GazeWire
📰 Alcohol Dampens Cancer Immunotherapy Efficacy in Preclinical Study
A new study reveals that moderate-to-heavy alcohol consumption cuts the effectiveness of anti-PD-1 immunotherapy by half in animal models.
gazewire.com
November 17, 2026 at 11:50 PM
1/4 Congratulations to Prof Robyn Jamieson, Dr Steven Eamegdool and the team on their latest research, published in #GeneTherapy journal @springernature.com.

You can follow the thread to learn more or read the full publication here: doi.org/10.1038/s414...
November 13, 2026 at 1:55 AM
Scientists at Johns Hopkins Medicine are moving closer to restoring hearing by regrowing inner-ear hair cells and repairing auditory nerves using gene therapy and immunology.

Read more about these breakthroughs: hopkinsmedicine.org

#HearingResearch #Science #GeneTherapy
Home
Johns Hopkins Medicine is a leading health system and academic institution in the U.S. Find information about doctors, locations, appointments, billing, research, education and more.
hopkinsmedicine.org
November 15, 2026 at 3:25 PM
A new translational architecture for protective and regenerative ocular #genetherapy

Guei-Sheung Liu, Danica Jovancevic, Pete A. Williams @petetheteapot.bsky.social EyeResearchAus @ki.se #glaucoma #retina

link.springer.com/article/10.1...
A new translational architecture for protective and regenerative ocular gene therapy - Molecular Neurodegeneration Advances
Molecular Neurodegeneration Advances -
link.springer.com
November 13, 2026 at 5:02 PM
🧬 Gene & Cell Therapy | #RareDiseases 🚀
#LucidQuest delivers sharp insights to help biotechs, investors & BD teams stay ahead in fast-moving markets.
📩 info@lqventures.com or http://dlvr.it/TWKgbB
#GeneTherapy #CellTherapy #Biotech #DueDiligence #InvestmentInsights
Gene & Cell Therapy and Rare Disease Intelligence - LucidQuest
Strategic insights for gene and cell therapy from R&D through commercialization. Primary KOL research, competitive analysis, and investment diligence in rare diseases.
dlvr.it
November 14, 2026 at 10:19 AM
At #SNO2026, UCSF neuro-oncology fellow Stefanie Stallard, MD, presented interim results from a UCSF-led phase 1/2 clinical trial using the DB107-RRV #GeneTherapy platform, showing that it can be safely delivered with radiation. Read more from @onclive.bsky.social: www.onclive.com/view/db107-r...
November 17, 2026 at 1:15 AM
Congratulations to Paloma Giangrande, PhD, on her appointment to a second term as Editor-in-Chief of Molecular Therapy Nucleic Acids. Her continued leadership will help drive innovation and growth in nucleic acid therapeutics.

Read more: https://bit.ly/4iJGXHD #RNA #GeneTherapy
November 9, 2026 at 5:15 PM
Heading to #Cell2026? Join Saisei Ventures' Sven Kili and Sarah Domoney for discussions on investment in #celltherapy, #genetherapy and #ATMP platforms, including advances in manufacturing and emerging technologies. @biosurgerysven.bsky.social

View the full agenda here: bit.ly/4za23VE
November 10, 2026 at 5:24 PM
Incredible news in neuroscience: experimental gene therapy delivered directly to the brain is making epileptic seizures nearly vanish for patients! This is a huge step forward, offering immense hope. ✨ #GeneTherapy #EpilepsyResearch #MedicalBreakthrough
Epileptic seizures nearly vanish after people receive experimental gene therapy in their brains
"Three people with epilepsy resistant to drug treatment saw the number of seizures they had per month fall by more than 90% after gene-laden viruses were infused directly into their brains as part of an early-stage clinical trial."
www.nature.com
November 10, 2026 at 1:00 PM
A gene therapy approaching its first human trial and an antibody already in dose-escalation will each be featured in a poster presentation at CTAD.

Link as first comment.

#longevity #geroscience #genetherapy #antibodytherapy #clinicaltrials
November 9, 2026 at 12:25 PM
🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TWFX7j #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT
November 8, 2026 at 7:07 PM
What’s shaping CVC investments for 2025? Key trends: AI/ML, Gene Therapy, and a focus on Immune Disorders & Neurodegenerative Diseases. Curious for more? 📥 Download the full report for insights! http://dlvr.it/TWH2CJ
#CVC #InvestingInInnovation #VentureCapital #GeneTherapy #AI
BioPharma (+ Google) Corporate Venture Capital Investment Trends: Who is leading in 2025?
Get instant access to a concise analysis of 22 BioPharma (+ Google) CVCs and their portfolios. In minutes, you’ll see where strategic capital is flowing across Technology and Therapy Areas—and how 2025 trends compare to 2023. What’s inside: Clear mapping of CVC focus by Technology and Therapy Areas Trend shifts vs. 2023 to validate your thesis Actionable insights to spot momentum early How it works: Fill out the form to receive your report immediately. Questions or feedback? info@lqventures.com LucidQuest empowers BioPharma executives and Life Sciences investors with up-to-date analysis. Stay tuned for 2025 deep dives on Cell & Gene Therapy, Digital Health, Oncology & Hematology, and more.
dlvr.it
November 10, 2026 at 7:05 PM
🏥 Zayed Centre for Research Marks Seven Years of Rare Disease Innovation

The Zayed Centre for Research into Rare Disease in Children (ZCR) is celebrating seven years of operations in London.

🔗 Read the full story on GazeWire

#Health #Biotech #GeneTherapy #GazeWire
🏥 Zayed Centre for Research Marks Seven Years of Rare Disease Innovation
The Zayed Centre for Research into Rare Disease in Children (ZCR) is celebrating seven years of operations in London.
gazewire.com
November 10, 2026 at 9:55 AM
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more news.. statnews.com/pharmalot/20... #pharma #weight #obesity #Medicare #genetherapy #FDA #Novartis #Lilly #Teva #UK
Pharmalittle: We're reading about a Novartis heart drug, BIO fighting a Trump program, and more
Novartis is largely abandoning a drug once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and deaths
statnews.com
November 9, 2026 at 2:44 PM